CIK 0001637715 · <br>Emerging growth company
OnKure Therapeutics, Inc.
Sign in to watch- Ticker
- OKUR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472309515
- Phone
- (720) 307-2892
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
- Former names
- Reneo Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,157
- in 2 filings
Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | Jansen Valerie Malyvanh Director | Grant or award · Stock Option (right to buy) | +7,650 | 7,650 | ||
| 2026-06-04 | Carruthers R Michael Director | Grant or award · Stock Option (right to buy) | +7,650 | 7,650 | ||
| 2026-06-04 | Ratcliffe Liam Director | Grant or award · Stock Option (right to buy) | +1,275 | 1,275 | ||
| 2026-06-04 | GREY MICHAEL G Director | Grant or award · Stock Option (right to buy) | +7,650 | 7,650 | ||
| 2026-06-04 | Mathers Edward T Director | Grant or award · Stock Option (right to buy) | +7,650 | 7,650 | ||
| 2026-04-01 | Hartley Dylan Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2026-04-01 | Agresta Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2026-04-01 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2026-04-01 | Saccomano Nicholas A President and CEO | Grant or award · Employee Stock Option (right to buy) | +330,000 | 330,000 | ||
| 2026-03-31 | Ratcliffe Liam Director | Grant or award · Stock Option (right to buy) | +15,300 | 15,300 | ||
| 2026-03-23 | Leverone Jason A. Chief Financial Officer | Sale | −301 | $4.16 | $1K | 16,000 |
| 2026-03-23 | Saccomano Nicholas A President and CEO | Sale | −86 | $4.16 | $357 | 7,333 |
| 2025-12-31 | Manke Isaac Director | Grant or award | +5,258 | 20,583 | ||
| 2025-12-31 | Mathers Edward T Director | Grant or award | +3,911 | 15,310 | ||
| 2025-12-22 | Leverone Jason A. Chief Financial Officer | Sale | −302 | $2.97 | $896 | 16,301 |
| 2025-12-22 | Saccomano Nicholas A President and CEO | Sale | −87 | $2.97 | $258 | 7,419 |
| 2025-09-30 | Manke Isaac Director | Grant or award | +5,545 | 15,325 | ||
| 2025-09-30 | Mathers Edward T Director | Grant or award | +4,125 | 11,399 | ||
| 2025-09-22 | Leverone Jason A. Chief Financial Officer | Sale | −303 | $2.62 | $795 | 12,603 |
| 2025-09-22 | Saccomano Nicholas A President and CEO | Sale | −88 | $2.62 | $231 | 3,506 |
Page 3 of 8 · 154 trades